PD-L1 expression testing in non-small cell lung cancer

In recent years, immunotherapy has revolutionized and changed the standard of care in patients with advanced non-small cell lung cancer (NSCLC). Immune checkpoint inhibitors, fundamentally those that act by blocking the programmed cell death receptor-1 (PD-1) and its ligand the programmed cell death...

Descripción completa

Detalles Bibliográficos
Autores principales: Teixidó, Cristina, Vilariño, Noelia, Reyes, Roxana, Reguart, Noemí
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2018
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898658/
https://www.ncbi.nlm.nih.gov/pubmed/29662547
http://dx.doi.org/10.1177/1758835918763493

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5898658/
https://www.ncbi.nlm.nih.gov/pubmed/29662547
http://dx.doi.org/10.1177/1758835918763493

Ejemplares similares